A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Cinolazepam
Metildigoxin
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Metildigoxin.
Cinolazepam
Gastric inhibitory polypeptide
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Gastric inhibitory polypeptide.
Cinolazepam
Tirzepatide
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Tirzepatide.
Cinolazepam
Englitazone
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Englitazone.
Cinolazepam
Taspoglutide
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Taspoglutide.
Cinolazepam
Semaglutide
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Semaglutide.
Cinolazepam
Metahexamide
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Metahexamide.
Cinolazepam
Guar gum
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Guar gum.
Cinolazepam
Carbutamide
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Carbutamide.
Cinolazepam
Remogliflozin etabonate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Remogliflozin etabonate.
Cinolazepam
Balaglitazone
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Balaglitazone.
Cinolazepam
Sotagliflozin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Sotagliflozin.
Cinolazepam
Evogliptin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Evogliptin.
Cinolazepam
Anagliptin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Anagliptin.
Cinolazepam
Gemigliptin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Gemigliptin.
Cinolazepam
Carmegliptin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Carmegliptin.
Cinolazepam
Omarigliptin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Omarigliptin.
Cinolazepam
Teneligliptin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Teneligliptin.
Cinolazepam
2,4-thiazolidinedione
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with 2,4-thiazolidinedione.
Cinolazepam
Tofogliflozin
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Tofogliflozin.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3